BiOrion is a Dutch biopharmaceutical drug discovery company involved in developing targeted therapeutics and companion imaging diagnostics for myofibroblast-associated diseases, such as hepatic fibrosis, renal fibrosis,  cardiac fibrosis, idiopathic pulmonary fibrosis and fibrosis-associated cancers such as pancreatic cancer and glioma. 

BiOrion's platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides. PDGF is one of the main drivers of fibrosis, and its receptor is specifically over-expressed on the key pathogenic cells: the myofibroblasts. This allows cell-specific targeting of diagnostic labels and (existing) antifibrotic drugs.

BiOrion is presently engaged in research collaborations with major pharmaceutical companies on 2 of its drug development programs. 

Latest News .......

BiOrion at AASLD, San Francisco, 2015
When: November 12-17, 2015

Drug development at BiOrion is made possible by



  • Register

Learn about fibrosis

Fibrosis is dysregulated wound healing. It is the consequence of chronic tissue injury and inflammation, resulting in repetitive formation of extracellular matrix such as collagen, that in turn leads to architectural disruption and organ failure and ultimately to death. The primary cells responsible for fibrosis are myofibroblasts ....

 Read More


PDGF is one of many growth factors that regulate cell growth and division. It is also a prominent stimulator of fibroblast proliferation during fibrosis. In liver fibrosis, PDGF is the most important mediator involved in the proliferation and activation of hepatic stellate cells, which transform subsequently into myofibroblasts....

Read More



BiOrion's core technology is based on proprietary PDGF-ß-receptor binding bicyclic octa-peptides, derived from the amino acid binding sequence of its natural ligand PDGF-BB. This bicyclic peptide can be conjugated to (antifibrotic) drugs (e.g. BOT191) or they can be incorporated onto liposomes containing....

  • fr-FR
  • English (UK)